Savara Inc. (SVRA) Says FDA Will Miss Molgramostim BLA Date

Savara Inc. (SVRA) announced the FDA will miss the November 22, 2026 PDUFA target date for its molgramostim BLA for autoimmune PAP. The review is ongoing, but no revised action date was provided. This is a regulatory timing setback for Savara's lead program.

Original reporting
Published Nov 20, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 20, 2026, 1:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Savara Inc. (SVRA) Says FDA Will Miss Molgramostim BLA Date — source image
Decision brief

The 30-second read

$SVRABearishMed
01

Why it matters

The missed PDUFA target introduces uncertainty about the approval timeline, which can depress the stock until a new date is set.

02

Market read

Regulatory timing news for a small‑cap biotech is highly relevant to traders with exposure to SVRA or the broader rare‑disease sector.

03

What to watch

Potential for accelerated review if additional data are submitted; market may have over‑reacted to the timing notice.

Relevance 7/10Novelty 7/10Timing: today

Background

Savara Inc. (SVRA) is a clinical‑stage biotech focused on rare lung diseases. Molgramostim is its lead candidate for autoimmune pulmonary alveolar proteinosis.

Company-level read

Ticker impact

$SVRABearishHigh confidence
Context

FDA announced it will not meet the Nov 22, 2026 PDUFA target for Savara's molgramostim BLA, creating a regulatory timing setback.

Expected impact

likely downward pressure as investors price in the extended review timeline

Evidence & confidence

Regulatory timing delays for a biotech's pivotal BLA are material and often trigger short-term sell‑offs.

Market effects

Biotech sector may see heightened scrutiny on pending BLAs, modestly affecting peer valuations.

U.S. biotech investors likely adjust positions; limited broader market effect.

Minimal global impact beyond niche biotech investors.

Counterpoint

If the FDA ultimately grants approval, the delay could be a buying opportunity at a lower price.

Key entities

  • Savara Inc.

    Biotech developer of molgramostim.

  • FDA

    U.S. Food and Drug Administration overseeing the BLA review.

Related articles

$SVRAMed

FDA to miss deadline on Savara's rare lung disease drug approval

Savara Inc. announced the FDA will miss its November 22 deadline to decide on its rare lung disease drug, molgramostim. The company's shares fell 16% in premarket trading. The FDA did not provide a new decision date, and Savara's application remains under review. Molgramostim is an experimental treatment for autoimmune pulmonary alveolar proteinosis, with no FDA-approved treatments currently available.

$SVRAHighAI 9/10

Why is Savara stock plunging today?

Savara (SVRA) stock fell 21.7% pre-market after the FDA delayed its decision on molgramostim, a treatment for a rare lung disease, without setting a new timeline. The stock had risen to $5.21 ahead of the expected decision. Analysts maintain Buy ratings with targets of $10-$11, but uncertainty looms. The broader market decline also pressured the stock, which traded at $4.08, near its 52-week low.

$SVRAMed

FDA delays decision on Savara’s autoimmune PAP treatment

Savara Inc. (SVRA) reported the FDA delayed its decision on the company's molgramostim treatment for autoimmune PAP, missing the November 2026 target date. The FDA is still reviewing the application and has not set a new timeline. Savara's CEO expressed commitment to working with the agency. Molgramostim is an investigational treatment for a rare lung disease, not yet approved by the FDA.

$SVRAMedAI 8/10

Savara Reports Molgramostim Benefits in Exploratory Lung Study

Savara Inc. (SVRA) reported improvements in lung function and imaging measures in a small subgroup of patients with autoimmune pulmonary alveolar proteinosis (aPAP) treated with molgramostim, according to a retrospective analysis presented at CHEST 2026. The analysis included 11 patients and showed a 12.7 mmHg improvement in the alveolar-arterial oxygen gradient for molgramostim recipients compared to 0.3 mmHg for placebo. The company noted the findings are exploratory and not definitive.